Axsome Therapeutics, Inc. AXSM
Set alert
As of Nov 3, 12:08 PM ET
- YTD
- -21.38%
- 1 year
- +5.78%
- Open
- 136.88
- Prev close
- 136.01
- Mkt cap
- 7.55B
- Vol
- 726.03K
- Avg vol
- 810.47K
- EPS
- -3.03
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 136.88
- High
- 145.50
- Forward P/E
- 32.37
- Beta
- 0.83
- Short ratio
- 3.67
- Inst. own
- 74.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 22, 2027
- 50-d avg
- 184.76
- 200-d avg
- 199.33
- 1y target
- 277.86
5D chart
Events in this range
- Nov 2, 2026Earnings: -0.25; estimate -0.63425; surprise 60.58%
Signals (85)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 10:55 AM | 1 hour ago |
| MACD: Sell Signal | Nov 3, 10:25 AM | 1 hour ago |
| SMA: Bearish | Nov 3, 10:20 AM | 1 hour ago |
| RSI: Overbought | Nov 3, 9:30 AM | 2 hours ago |
| RSI: Overbought | Nov 2, 3:40 PM | 20 hours ago |
| RSI: Overbought | Nov 2, 3:05 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 2:30 PM | 21 hours ago |
| MACD: Buy Signal | Nov 2, 2:30 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 2:05 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 1:30 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 1:30 PM | 22 hours ago |
| MACD: Sell Signal | Nov 2, 1:30 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 1:15 PM | 22 hours ago |
| MACD: Buy Signal | Nov 2, 1:15 PM | 22 hours ago |
| MACD: Sell Signal | Nov 2, 1:10 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 12:50 PM | 23 hours ago |
| SMA: Bullish | Nov 2, 11:45 AM | 1 day ago |
| SMA: Bullish | Nov 2, 11:15 AM | 1 day ago |
| MACD: Buy Signal | Nov 2, 11:05 AM | 1 day ago |
| MACD: Sell Signal | Nov 2, 10:55 AM | 1 day ago |
Newest 20 of 85.
News
-
52 minutes ago benzinga.com
UBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239
UBS analyst Ashwani Verma maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $256 to $239.
-
2 hours ago benzinga.com
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $295 to $273.
-
2 hours ago benzinga.com
Guggenheim Maintains Buy on Axsome Therapeutics, Lowers Price Target to $250
Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $275 to $250.
5 hours ago globenewswire.com
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today…
-
5 hours ago benzinga.com
Baird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220
Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $246 to $220.
17 hours ago seekingalpha.com
Axsome Therapeutics: Sentiment Meets Reality After Q3 (Rating Upgrade)
Axsome Therapeutics (AXSM) is upgraded to 'Hold' as its valuation now better reflects commercial realities post-ADA approval. AUVELITY's ADA launch is progressing slower than hoped, with incremental…
22 hours ago seekingalpha.com
Axsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call Transcript
Axsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call Transcript
23 hours ago benzinga.com
Dow Rises 1%, Oil Sinks 7% on Iran Peace Hopes: Stock Market Today
Oil tumbles on renewed U.S.-Iran diplomacy, pulling Treasury yields lower and lifting the Dow, airlines and Amazon while energy stocks lag.
1 day ago marketbeat.com
What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
Axsome Therapeutics NASDAQ: AXSM reported third-quarter revenue growth of 52% year over year, driven primarily by continued expansion of AUVELITY sales in major depressive disorder and Alzheimer's…
1 day ago zacks.com
Axsome (AXSM) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
1 day ago zacks.com
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.94 per share a year ago.
1 day ago benzinga.com
Axsome Therapeutics Q3 2026 Earnings Call Transcript
Axsome Therapeutics (NASDAQ:AXSM) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
-
1 day ago benzinga.com
Axsome Therapeutics Q3 EPS $(0.25) Beats $(0.56) Estimate, Sales $259.691M Beat $249.929M Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.56) by 55.36 percent. This is a 73.4 percent increase over losses of…
1 day ago globenewswire.com
Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY ® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI ® 3Q…
1 day ago benzinga.com
Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test
Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…
6 days ago fool.com
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility
Axsome Therapeutics (AXSM -1.29%) primarily discovers, develops, and exclusively commercializes innovative medical treatments targeting numerous central nervous system disorders domestically.
1 week ago zacks.com
Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
1 week ago benzinga.com
Piper Sandler Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $238
Piper Sandler analyst David Amsellem maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and lowers the price target from $258 to $238.
1 week ago fool.com
2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)
Axsome Therapeutics should expand its approved lineup while not facing the threat of generic competition through 2036. Eli Lilly is a leader in its core market and could diversify its lineup over the…
1 week ago zacks.com
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.
1 week ago benzinga.com
Top 3 Health Care Stocks That Could Blast Off In October
Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
3 weeks ago fool.com
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?
Axsome sees at least $8 billion in potential peak Auvelity sales. Additional drugs and pipeline candidates could fuel long-term growth.
3 weeks ago zacks.com
4 CNS Drug Stocks Worth Watching This World Mental Health Day
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
-
3 weeks ago benzinga.com
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $297 to $295.
3 weeks ago fool.com
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
Axsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market. Moderna is moving beyond its pandemic roots by advancing a deep…
3 weeks ago globenewswire.com
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today…
1 month ago fool.com
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders. Vertex Pharmaceuticals remains a highly profitable giant with…
-
1 month ago benzinga.com
Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267
Deutsche Bank analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $280 to $267.
1 month ago benzinga.com
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
-
1 month ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $251 to $247.
1 month ago benzinga.com
$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today
Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 24.39% on an annualized basis producing an average annual return of 37.87%. Currently, Axsome Therapeutics has…
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
1 month ago benzinga.com
Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285
Truist Securities analyst Srikripa Devarakonda maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200 to $285.
-
1 month ago benzinga.com
Axsome Therapeutics Highlights Alzheimer’s Agitation Impact In Shared Goals Survey
The Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disruptedNinety-seven percent of care…
1 month ago globenewswire.com
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day
The Shared Goals: Navigating Alzheimer's Agitation survey finds that Alzheimer's disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care…
1 month ago benzinga.com
5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In
U.S. stocks ended mixed; the Dow had its worst week since March. Benzinga highlights top picks from five accurate analysts, including ON, AXSM and LLY.
1 month ago defenseworld.net
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
Axsome Therapeutics (NASDAQ: AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in…
1 month ago defenseworld.net
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
Axsome Therapeutics (NASDAQ: AXSM) executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th…
1 month ago marketbeat.com
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer's Launch Gains Traction
Axsome Therapeutics NASDAQ: AXSM executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in…
-
1 month ago benzinga.com
Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target
Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $258 price target.
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $290 price target.
-
2 months ago benzinga.com
Axsome Therapeutics Dosed First Patient in SUMMIT Phase 3 Trial of AXS-05 For Smoking Cessation
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been…
-
2 months ago benzinga.com
Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years
Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 46.84% on an annualized basis producing an average annual return of 58.59%. Currently, Axsome Therapeutics has a…
2 months ago benzinga.com
If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today
Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 26.64% on an annualized basis producing an average annual return of 40.19%. Currently, Axsome Therapeutics has…
2 months ago benzinga.com
Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downgrades on analyst ratings page.
3 months ago benzinga.com
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday
Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
3 months ago benzinga.com
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.
-
3 months ago benzinga.com
9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
5 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
-
5 months ago benzinga.com
'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive
Health officials explored restricting specific antidepressants among SSRI drugs-sources